Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood (Nasdaq: IRWD) presented LANDMARK survey and clinical updates at DDW 2026 highlighting unmet needs in short bowel syndrome with intestinal failure (SBS-IF).
HCPs prioritized reducing days on TPN (46.4%) and cited central line infections (59.8%) and catheter-related challenges (48.2%) as major burdens. Apraglutide long-term safety remained consistent; linaclotide showed tolerability and symptom benefit across analyses.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will present LANDMARK survey findings and STARS long-term safety data for apraglutide at Digestive Disease Week® 2026, May 2–5 in Chicago. Presentations also cover linaclotide analyses in IBS-C, CIC and pediatric functional constipation, highlighting HCP perspectives on TPN burden in SBS-IF.
Ironwood Pharmaceuticals (NASDAQ: IRWD) said management will take part in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11 at 4:00 p.m. ET. A live webcast will be available via the company’s Investors & Media website and a replay will follow.
Ironwood (Nasdaq: IRWD) reported 2025 results and 2026 guidance. 2025 total revenue was $296.2M, GAAP net income $24.0M, adjusted EBITDA $138.1M, and cash of $215.5M. LINZESS EUTRx demand grew 11% YoY. 2026 guidance expects LINZESS U.S. net sales $1.125–$1.175B, total revenue $450–$475M, and adjusted EBITDA >$300M. Apraglutide STARS-2 Phase 3 design is finalized, with site initiations expected in Q2 2026.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its fourth quarter and full year 2025 investor update call and webcast at 8:30 a.m. ET on Wednesday, February 25, 2026. Participants may join by phone or listen via the company webcast.
Replay by telephone will be available starting ~11:30 a.m. ET on February 25, 2026, through 11:59 p.m. ET on March 11, 2026. Conference ID and passcode for live and replay: 8188306. Visit the Investors & Media section at the company website to access the webcast.
Ironwood Pharmaceuticals (Nasdaq: IRWD) maintained FY2025 guidance and provided FY2026 guidance on January 2, 2026. For FY2026 the company forecasts LINZESS U.S. net sales of $1.125–$1.175 billion, total revenue of $450–$475 million, and adjusted EBITDA greater than $300 million. Ironwood ended Q4 2025 with more than $200 million in cash and cash equivalents. Management said the FY2026 LINZESS sales outlook reflects a lowered list price effective January 1, 2026, which reduces statutory inflationary rebates and is expected to raise net sales year-over-year. The company plans a confirmatory Phase 3 apraglutide trial for SBS-IF to start in H1 2026 and continues a strategic alternatives review.
Summary not available.
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported strong Q2 2025 results, with LINZESS U.S. net sales reaching $248 million, showing 17% growth year-over-year and 10% EUTRx demand growth. The company posted GAAP net income of $23.6 million ($0.15 per share basic) compared to a loss in Q2 2024.
Key financial metrics include total revenue of $85.2 million and adjusted EBITDA of $50.1 million. The company maintained its 2025 guidance, projecting LINZESS U.S. net sales of $800-850 million and total revenue of $260-290 million.
Ironwood is progressing with apraglutide development, finalizing Phase 3 trial design for FDA alignment in Q4 2025, while actively pursuing strategic alternatives review to maximize shareholder value.